To present the daily lives of people living with PKD and to make their voices heard by decision-makers, who will decide on public access and reimbursement for the only treatment available for PKD, the PKD Foundation of Canada invites you to answer a short survey which is available online. The results of this survey, completed in confidentiality, will be submitted to INESSS, the provincial entity responsible for the evaluation of medical treatments, for inclusion on the List of Medications of the Régie de l’assurance maladie du Québec (RAMQ).
The survey will be available until February 19, 2018.
The goal of this survey is to make decision-makers aware of what having access to this treatment option would mean to PKD patients, with the objective of helping them manage their disease and avoid other therapeutic alternatives.
Completion of the survey should take you 10 minutes or less.